Treatment of chronic wounds by local delivery of granulocyte-macrophage colony-stimulating factor in patients with neutrophil dysfunction

Pediatr Surg Int. 2002 Sep;18(5-6):517-20. doi: 10.1007/s00383-002-0733-3. Epub 2002 Jun 15.

Abstract

Chronic wounds are associated with considerable morbidity and prolonged hospitalizations. The availability of recombinant growth factors and cytokines provides a new modality for treatment of recalcitrant wounds. Granulocyte-macrophage colony-stimulating factor (GM-CSF), a growth protein for hematopietic cells, also enhances neutrophil and monocyte function and promotes keratinocyte proliferation. In three patients with inherited disorders associated with leukocyte dysfunction and non-healing wounds, topical application of GM-CSF resulted in complete wound closure within 1 to 4 weeks. A subcutaneous (s.c.) infusion pump for the local s.c. delivery of GM-CSF was also found to enhance healing. Local application of GM-CSF may thus promote wound closure in patients with impaired wound healing.

Publication types

  • Case Reports

MeSH terms

  • Administration, Topical
  • Adolescent
  • Child, Preschool
  • Drug Delivery Systems*
  • Female
  • Glycogen Storage Disease Type I / drug therapy*
  • Glycogen Storage Disease Type I / physiopathology
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage*
  • Granulomatous Disease, Chronic / drug therapy*
  • Granulomatous Disease, Chronic / physiopathology
  • Humans
  • Infusions, Intralesional
  • Male
  • Neutrophils / physiology
  • Recombinant Proteins
  • Wound Healing / drug effects*

Substances

  • Recombinant Proteins
  • sargramostim
  • Granulocyte-Macrophage Colony-Stimulating Factor